HC Wainwright Reaffirms Neutral Rating for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ:AGEN - Get Free Report)'s stock had its "neutral" rating restated by stock analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. HC Wainwright also issued estimates for Agenus' Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($2.18) EPS, FY2026 earnings at ($2.67) EPS, FY2027 earnings at ($2.38) EPS, FY2028 earnings at ($3.10) EPS and FY2029 earnings at ($1.90) EPS.

Other equities research analysts also recently issued reports about the company. Robert W. Baird increased their price target on Agenus from $3.00 to $4.00 and gave the stock a "neutral" rating in a report on Tuesday. StockNews.com raised Agenus from a "sell" rating to a "hold" rating in a report on Friday, March 21st. Finally, B. Riley reaffirmed a "buy" rating on shares of Agenus in a report on Monday, April 21st. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat.com, Agenus currently has a consensus rating of "Hold" and an average price target of $9.00.

Agenus Stock Up 3.0%

AGEN traded up $0.10 on Tuesday, reaching $3.48. The company's stock had a trading volume of 826,490 shares, compared to its average volume of 588,596. The stock has a 50 day moving average of $2.21 and a two-hundred day moving average of $2.91. The company has a market capitalization of $95.41 million, a price-to-earnings ratio of -0.31 and a beta of 1.48. Agenus has a fifty-two week low of $1.38 and a fifty-two week high of $19.69.

Agenus (NASDAQ:AGEN - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.61) by $0.58. The firm had revenue of $24.07 million during the quarter, compared to analyst estimates of $26.38 million. As a group, analysts anticipate that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Corton Capital Inc. purchased a new stake in Agenus during the 4th quarter worth about $36,000. Virtu Financial LLC bought a new stake in shares of Agenus in the 4th quarter valued at approximately $51,000. Apollon Wealth Management LLC bought a new stake in shares of Agenus in the 4th quarter valued at approximately $55,000. Bank of Montreal Can bought a new stake in shares of Agenus in the 4th quarter valued at approximately $69,000. Finally, Barclays PLC increased its holdings in shares of Agenus by 295.3% in the 3rd quarter. Barclays PLC now owns 27,813 shares of the biotechnology company's stock valued at $152,000 after acquiring an additional 20,777 shares during the last quarter. Hedge funds and other institutional investors own 61.46% of the company's stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.